KR20230043891A - 조혈 줄기 세포 이식으로 인한 이식편대숙주병의 치료 방법 - Google Patents

조혈 줄기 세포 이식으로 인한 이식편대숙주병의 치료 방법 Download PDF

Info

Publication number
KR20230043891A
KR20230043891A KR1020237005450A KR20237005450A KR20230043891A KR 20230043891 A KR20230043891 A KR 20230043891A KR 1020237005450 A KR1020237005450 A KR 1020237005450A KR 20237005450 A KR20237005450 A KR 20237005450A KR 20230043891 A KR20230043891 A KR 20230043891A
Authority
KR
South Korea
Prior art keywords
days
compound
group
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005450A
Other languages
English (en)
Korean (ko)
Inventor
청링 쳉
얀핑 자오
홍준 왕
웨이팅 종
징 리
징 자오
웨이나 리우
Original Assignee
베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 filed Critical 베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Publication of KR20230043891A publication Critical patent/KR20230043891A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237005450A 2020-07-22 2021-07-21 조혈 줄기 세포 이식으로 인한 이식편대숙주병의 치료 방법 Pending KR20230043891A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010713637 2020-07-22
CN202010713637.0 2020-07-22
PCT/CN2021/107575 WO2022017412A1 (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Publications (1)

Publication Number Publication Date
KR20230043891A true KR20230043891A (ko) 2023-03-31

Family

ID=79728482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005450A Pending KR20230043891A (ko) 2020-07-22 2021-07-21 조혈 줄기 세포 이식으로 인한 이식편대숙주병의 치료 방법

Country Status (11)

Country Link
US (1) US12702668B2 (cg-RX-API-DMAC7.html)
EP (1) EP4186508A4 (cg-RX-API-DMAC7.html)
JP (1) JP7803924B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230043891A (cg-RX-API-DMAC7.html)
CN (2) CN116322670A (cg-RX-API-DMAC7.html)
AU (1) AU2021313124A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001049A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186564A1 (cg-RX-API-DMAC7.html)
IL (1) IL299985A (cg-RX-API-DMAC7.html)
TW (2) TW202216691A (cg-RX-API-DMAC7.html)
WO (1) WO2022017412A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009568A (es) * 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
RS63503B1 (sr) * 2012-10-05 2022-09-30 Kadmon Corporation Llc Inhibitori rho kinaze
EP3504204A4 (en) 2016-08-26 2020-05-27 Lycera Corporation INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7311228B2 (ja) * 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
US10329282B2 (en) * 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法

Also Published As

Publication number Publication date
CA3186564A1 (en) 2022-01-27
JP2023535035A (ja) 2023-08-15
TWI868660B (zh) 2025-01-01
CN121846099A (zh) 2026-04-14
EP4186508A4 (en) 2024-10-16
BR112023001049A2 (pt) 2023-03-07
WO2022017412A1 (zh) 2022-01-27
AU2021313124A1 (en) 2023-03-09
CN116322670A (zh) 2023-06-23
EP4186508A1 (en) 2023-05-31
JP7803924B2 (ja) 2026-01-21
US12702668B2 (en) 2026-08-11
US20230285393A1 (en) 2023-09-14
IL299985A (en) 2023-03-01
TW202327609A (zh) 2023-07-16
TW202216691A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
US12582653B2 (en) Method for treating idiopathic pulmonary fibrosis
KR20210137086A (ko) 지방간 질환 및/또는 지방간염의 치료 방법
EP4186508A1 (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
KR102935436B1 (ko) 디아미노피리미딘 화합물을 사용한 기침 치료 방법
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
EP4591863A1 (en) Method for treating pneumoconiosis
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40062124B (en) Method for treating cough by using diaminopyrimidine compound
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40121343A (en) Method for treating idiopathic pulmonary fibrosis
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
CN113164487B (zh) 磷酸二酯酶抑制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902